File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX™ in healthy children

TitleA comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX™ in healthy children
Authors
Lau, YLVessey, SJRChan, ISFLee, TLHuang, LMLee, CYLin, TYLee, BWKwan, KKasim, SMChan, CYKaplan, KMDistefano, DJHarmon, ALGolie, AHartzel, JXu, JLi, SMatthews, HSadoff, JCShaw, A
KeywordsImmunogenicity
Varicella vaccination
Varicella zoster virus
Issue Date2002
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
Citation
Vaccine, 2002, v. 20 n. 23-24, p. 2942-2949 How to Cite?
DOI: http://dx.doi.org/10.1016/S0264-410X(02)00245-1
AbstractThis study compared safety, tolerability, and immunogenicity of the Oka/Merck varicella vaccine and VARILRIX™ [Oka-RIT strain SmithKline Beecham Biologicals] in healthy children 12-24 months of age. Subjects were randomized in this double blind study to receive either a single dose of Oka/Merck varicella vaccine, (∼50,000 plaque forming units (PFU), Group A or ∼16,000PFU, Group B) or 1 dose of VARILRIX™, (∼40,000PFU/dose, Group C). Safety profiles in each treatment group were similar. The proportions of subjects achieving a 6-week postvaccination titer ≥5 gpELISA units in Groups A, B or C were 97.1, 95.2 and 85.6%, respectively. © 2002 Elsevier Science Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/173455
ISSN
0264-410X
2023 Impact Factor: 4.5
2023 SCImago Journal Rankings: 1.342
ISI Accession Number ID
WOS:000177649400015
References
References in Scopus

 

DC FieldValueLanguage
dc.contributor.authorLau, YLen_US
dc.contributor.authorVessey, SJRen_US
dc.contributor.authorChan, ISFen_US
dc.contributor.authorLee, TLen_US
dc.contributor.authorHuang, LMen_US
dc.contributor.authorLee, CYen_US
dc.contributor.authorLin, TYen_US
dc.contributor.authorLee, BWen_US
dc.contributor.authorKwan, Ken_US
dc.contributor.authorKasim, SMen_US
dc.contributor.authorChan, CYen_US
dc.contributor.authorKaplan, KMen_US
dc.contributor.authorDistefano, DJen_US
dc.contributor.authorHarmon, ALen_US
dc.contributor.authorGolie, Aen_US
dc.contributor.authorHartzel, Jen_US
dc.contributor.authorXu, Jen_US
dc.contributor.authorLi, Sen_US
dc.contributor.authorMatthews, Hen_US
dc.contributor.authorSadoff, JCen_US
dc.contributor.authorShaw, Aen_US
dc.date.accessioned2012-10-30T06:31:58Z-
dc.date.available2012-10-30T06:31:58Z-
dc.date.issued2002en_US
dc.identifier.citationVaccine, 2002, v. 20 n. 23-24, p. 2942-2949en_US
dc.identifier.issn0264-410Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/173455-
dc.description.abstractThis study compared safety, tolerability, and immunogenicity of the Oka/Merck varicella vaccine and VARILRIX™ [Oka-RIT strain SmithKline Beecham Biologicals] in healthy children 12-24 months of age. Subjects were randomized in this double blind study to receive either a single dose of Oka/Merck varicella vaccine, (∼50,000 plaque forming units (PFU), Group A or ∼16,000PFU, Group B) or 1 dose of VARILRIX™, (∼40,000PFU/dose, Group C). Safety profiles in each treatment group were similar. The proportions of subjects achieving a 6-week postvaccination titer ≥5 gpELISA units in Groups A, B or C were 97.1, 95.2 and 85.6%, respectively. © 2002 Elsevier Science Ltd. All rights reserved.en_US
dc.languageengen_US
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccineen_US
dc.relation.ispartofVaccineen_US
dc.subjectImmunogenicity-
dc.subjectVaricella vaccination-
dc.subjectVaricella zoster virus-
dc.subject.meshAntibodies, Viral - Blooden_US
dc.subject.meshChickenpox Vaccine - Adverse Effects - Immunologyen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshDrug Toleranceen_US
dc.subject.meshEnzyme-Linked Immunosorbent Assayen_US
dc.subject.meshFemaleen_US
dc.subject.meshHerpesvirus 3, Human - Immunologyen_US
dc.subject.meshHumansen_US
dc.subject.meshInfanten_US
dc.subject.meshMaleen_US
dc.subject.meshSafetyen_US
dc.subject.meshVaccines, Attenuated - Adverse Effects - Immunologyen_US
dc.titleA comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX™ in healthy childrenen_US
dc.typeArticleen_US
dc.identifier.emailLau, YL:lauylung@hkucc.hku.hken_US
dc.identifier.authorityLau, YL=rp00361en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/S0264-410X(02)00245-1en_US
dc.identifier.pmid12126906en_US
dc.identifier.scopuseid_2-s2.0-0037178307en_US
dc.identifier.hkuros75704-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0037178307&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume20en_US
dc.identifier.issue23-24en_US
dc.identifier.spage2942en_US
dc.identifier.epage2949en_US
dc.identifier.isiWOS:000177649400015-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridLau, YL=7201403380en_US
dc.identifier.scopusauthoridVessey, SJR=7004332645en_US
dc.identifier.scopusauthoridChan, ISF=35358702000en_US
dc.identifier.scopusauthoridLee, TL=8508917400en_US
dc.identifier.scopusauthoridHuang, LM=7404736430en_US
dc.identifier.scopusauthoridLee, CY=7410150061en_US
dc.identifier.scopusauthoridLin, TY=26326075000en_US
dc.identifier.scopusauthoridLee, BW=7405437980en_US
dc.identifier.scopusauthoridKwan, K=36937078200en_US
dc.identifier.scopusauthoridKasim, SM=6701573367en_US
dc.identifier.scopusauthoridChan, CY=36338941900en_US
dc.identifier.scopusauthoridKaplan, KM=35403378000en_US
dc.identifier.scopusauthoridDistefano, DJ=6602180111en_US
dc.identifier.scopusauthoridHarmon, AL=7005823511en_US
dc.identifier.scopusauthoridGolie, A=6506018038en_US
dc.identifier.scopusauthoridHartzel, J=36956308200en_US
dc.identifier.scopusauthoridXu, J=7408556813en_US
dc.identifier.scopusauthoridLi, S=7409203132en_US
dc.identifier.scopusauthoridMatthews, H=7202534295en_US
dc.identifier.scopusauthoridSadoff, JC=35466357200en_US
dc.identifier.scopusauthoridShaw, A=7402249224en_US
dc.identifier.issnl0264-410X-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats